← Leaderboards
Renee D Stapleton
University Of Vermont & St Agric College
$9,821,305
Attributed
$24,013,271
Total exposure
11
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $5.5M · FY2008–24$10M$7.5M$5M$2.5M$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$24,013,271 · 11
By mechanism
R01$9,390,516 · 3
UH3$8,723,851 · 1
UG3$2,341,858 · 1
R42$2,275,472 · 1
K23$625,860 · 1
P20$480,396 · 2
Top collaborators
- Dale Murray Needham9 shared
- Michael J Boeckh6 shared
- Daniel Clark Files6 shared
- Abhijit Prakash Limaye6 shared
- Gordon D Rubenfeld6 shared
- Daren Keith Heyland5 shared
- Michael J Toth5 shared
- Matthew E Poynter3 shared
Most similar at University Of Vermont & St Agric College
Same institution · by research overlap
- Benjamin Lee$2,697,392
- Polly E. Parsons$20,000
Others in their field
Top investigators on “Critical Illness”
- Jonathan Michael Dean · University Of Utah$52,116,961
- Robert H Tukey · University Of California San Diego$50,968,168
- Mark R Farfel · Hugo W. Moser Res Inst Kennedy Krieger$37,361,278
- Tatiana M. Foroud · Indiana Univ-Purdue Univ At Indianapolis$35,137,697
- Steven M Greenberg · Massachusetts General Hospital$31,323,044
- Natalia S Rost · Massachusetts General Hospital$31,323,044
Research focus
Critical IllnessFundingEnrollmentResourcesResearch PersonnelIncidenceRandomized Controlled TrialsCaringLungSurvivorsCollaborationsMechanical VentilationBasePositioning AttributeSupplementationClinical PracticeInsightInnovationTreatment As UsualRandomized TrialAcute Respiratory FailureIntravenousClinical CareInflammation
Grant awards (34)
1/2 Ganciclovir to Prevent Reactivation of Cytomegalovirus in Patients with Acute Respiratory Failure and Sepsis$2,170,027
UH3 · FY2024 · HL
1/2 Ganciclovir to Prevent Reactivation of Cytomegalovirus in Patients with Acute Respiratory Failure and Sepsis$2,120,121
UH3 · FY2023 · HL
1/2 Ganciclovir to Prevent Reactivation of Cytomegalovirus in Patients with Acute Respiratory Failure and Sepsis$2,216,758
UH3 · FY2022 · HL
1/2 Ganciclovir to Prevent Reactivation of Cytomegalovirus in Patients with Acute Respiratory Failure and Sepsis$1,503,461
UH3 · FY2021 · HL
Effects of Exercise on Inflammation-Induced Lung and Muscle Injury in Critical Illness (NEXIS-FLAME)$747,278
R01 · FY2021 · HL · contact PI
1/2 Ganciclovir to Prevent Reactivation of Cytomegalovirus in Patients with Acute Respiratory Failure and Sepsis$713,484
UH3 · FY2021 · HL
Nutrition and Exercise in Critical Illness (The NEXIS Trial): A Randomized Trial of Combined Cycle Ergometry and Amino Acids in the ICU$687,902
R01 · FY2021 · HL · contact PI
Effects of Exercise on Inflammation-Induced Lung and Muscle Injury in Critical Illness (NEXIS-FLAME)$63,581
R01 · FY2021 · HL · contact PI
1/2 Ganciclovir to Prevent Reactivation of Cytomegalovirus in Patients with Acute Respiratory Failure and Sepsis$2,341,858
UG3 · FY2020 · HL
Effects of Exercise on Inflammation-Induced Lung and Muscle Injury in Critical Illness (NEXIS-FLAME)$757,241
R01 · FY2020 · HL · contact PI
Novel Arm Restraint For Critically Ill Patients To Reduce Immobility, Sedation, Agitation and Cognitive Impairment$733,343
R42 · FY2020 · AG · contact PI
Nutrition and Exercise in Critical Illness (The NEXIS Trial): A Randomized Trial of Combined Cycle Ergometry and Amino Acids in the ICU$709,833
R01 · FY2020 · HL · contact PI
Improving Palliative Care for Older Seriously Hospitalized Patients and Their Families: A Randomized Trial of an Informed Assent Communication Intervention about CPR$526,389
R01 · FY2020 · AG · contact PI
Novel Arm Restraint For Critically Ill Patients To Reduce Immobility, Sedation, Agitation and Cognitive Impairment$374,498
R42 · FY2020 · AG · contact PI
Effects of Exercise on Inflammation-Induced Lung and Muscle Injury in Critical Illness (NEXIS-FLAME)$63,581
R01 · FY2020 · HL · contact PI
Novel Arm Restraint For Critically Ill Patients To Reduce Immobility, Sedation, Agitation and Cognitive Impairment$795,824
R42 · FY2019 · AG · contact PI
Effects of Exercise on Inflammation-Induced Lung and Muscle Injury in Critical Illness (NEXIS-FLAME)$778,606
R01 · FY2019 · HL · contact PI
Nutrition and Exercise in Critical Illness (The NEXIS Trial): A Randomized Trial of Combined Cycle Ergometry and Amino Acids in the ICU$707,635
R01 · FY2019 · HL · contact PI
Improving Palliative Care for Older Seriously Hospitalized Patients and Their Families: A Randomized Trial of an Informed Assent Communication Intervention about CPR$501,090
R01 · FY2019 · AG · contact PI
Effects of Exercise on Inflammation-Induced Lung and Muscle Injury in Critical Illness (NEXIS-FLAME)$803,292
R01 · FY2018 · HL
Nutrition and Exercise in Critical Illness (The NEXIS Trial): A Randomized Trial of Combined Cycle Ergometry and Amino Acids in the ICU$701,294
R01 · FY2018 · HL · contact PI
Improving Palliative Care for Older Seriously Hospitalized Patients and Their Families: A Randomized Trial of an Informed Assent Communication Intervention about CPR$528,115
R01 · FY2018 · AG · contact PI
Novel Arm Restraint For Critically Ill Patients To Reduce Immobility, Sedation, Agitation and Cognitive Impairment$371,807
R42 · FY2018 · AG · contact PI
Nutrition and Exercise in Critical Illness (The NEXIS Trial): A Randomized Trial of Combined Cycle Ergometry and Amino Acids in the ICU$734,325
R01 · FY2017 · HL · contact PI
Improving Palliative Care for Older Seriously Hospitalized Patients and Their Families: A Randomized Trial of an Informed Assent Communication Intervention about CPR$502,423
R01 · FY2017 · AG · contact PI
Improving Palliative Care for Older Seriously Hospitalized Patients and Their Families: A Randomized Trial of an Informed Assent Communication Intervention about CPR$577,931
R01 · FY2016 · AG · contact PI
Pharmaconutrients as Therapies for Critical Illness: Zinc in Severe Sepsis$156,465
K23 · FY2014 · HL · contact PI
Pharmaconutrients as Therapies for Critical Illness: Zinc in Severe Sepsis$156,465
K23 · FY2013 · HL · contact PI
Pharmaconutrients as Therapies for Critical Illness: Zinc in Severe Sepsis$156,465
K23 · FY2012 · HL · contact PI
Pharmaconutrients as Therapies for Critical Illness: Zinc in Severe Sepsis$156,465
K23 · FY2011 · HL · contact PI
EPA & DHA IN CRITICALLY ILL PATIENTS WITH SEPSIS AND CONTROLS$135,219
M01 · FY2010 · RR · contact PI
FISH OIL ON LUNG AND SYSTEMIC INFLAMMATION IN PATIENTS WITH ACUTE LUNG INJURY$244,721
P20 · FY2009 · RR · contact PI
EPA & DHA IN CRITICALLY ILL PATIENTS WITH SEPSIS AND CONTROLS$40,099
M01 · FY2009 · RR · contact PI
FISH OIL ON LUNG AND SYSTEMIC INFLAMMATION IN PATIENTS WITH ACUTE LUNG INJURY$235,675
P20 · FY2008 · RR · contact PI